TEK2day FINANCE About TEK2day Finance

Journey Medical Corporation (DERM)

NCM · Healthcare · Drug Manufacturers - Specialty & Generic

$7.23 +1.97%

Closing price as of 2026-09-11 · Source: TEK2day Finance

1-Year Price History -1.6% over period
$10$8$7$5$4 2025-092025-122026-032026-062026-09

Key Metrics

Market Cap
$160.7M
Shares Outstanding
22.2M
P/S (TTM)
2.4x
Exchange
NCM
Currency
USD

About Journey Medical Corporation

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Quarterly Financials

Metric2025-09-302025-12-312026-03-312026-06-30
Revenue17.6M16.1M16.0M18.5M
Gross Profit11.9M10.6M9.7M12.4M
Operating Income(1.5M)(443K)(1.5M)456K
Net Income(2.3M)(1.2M)(2.2M)(312K)
Diluted EPS$-0.09N/A$-0.08$-0.01

Annual Financials

Metric2022-12-312023-12-312024-12-312025-12-31
Revenue73.7M79.2M56.1M61.9M
Gross Profit42.9M56.3M35.3M40.9M
Operating Income(27.5M)1.1M(18.2M)(8.2M)
Net Income(29.6M)(3.9M)(14.7M)(11.4M)
Diluted EPS$-1.69$-0.21$-0.72N/A
Want live quotes, estimates, SEC filings, and CEO analytics for DERM?
The free TEK2day terminal runs in your browser — type /DERM to get started.
Open DERM in the Terminal →